Moderna asegura tener 'millones' de vacunas almacenadas en EU

30 de Noviembre de 2024

Moderna asegura tener ‘millones’ de vacunas almacenadas en EU

FRANCE-HEALTH-VIRUS-MODERNA-VACCINE

This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic. (Photo by JOEL SAGET / AFP) / �The erroneous mention[s] appearing in the metadata of this photo by JOEL SAGET has been modified in AFP systems in the following manner: [This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic.] instead of [This illustration picture taken in a studio in Paris on November 16, 2020, shows a syringe and a vial with the logo of US biotech firm Moderna.]. Please immediately remove the erroneous mention[s] from all your online services and delete it (them) from your servers. If you have been authorized by AFP to distribute it (them) to third parties, please ensure that the same actions are carried out by them. Failure to promptly comply with these instructions will entail liability on your part for any continued or post notification usage. Therefore we thank you very much for all your attention and prompt action. We are sorry for the inconvenience this notification may cause and remain at your disposal for any further information you may require.�

/

JOEL SAGET/AFP

This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic. (Photo by JOEL SAGET / AFP) / “The erroneous mention[s] appearing in the metadata of this photo by JOEL SAGET has been modified in AFP systems in the following manner: [This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic.] instead of [This illustration picture taken in a studio in Paris on November 16, 2020, shows a syringe and a vial with the logo of US biotech firm Moderna.]. Please immediately remove the erroneous mention[s] from all your online services and delete it (them) from your servers. If you have been authorized by AFP to distribute it (them) to third parties, please ensure that the same actions are carried out by them. Failure to promptly comply with these instructions will entail liability on your part for any continued or post notification usage. Therefore we thank you very much for all your attention and prompt action. We are sorry for the inconvenience this notification may cause and remain at your disposal for any further information you may require.”
Foto: AFP

Asegura que las dosis están listas para ser entregadas a las autoridades estadounidenses en cuanto se autorice su comercialización

El director general de la biotecnológica estadounidense

Moderna

dijo el martes a los europeos que la prolongación de las negociaciones para la compra de su vacuna contra el covid-19 puede retrasar las entregas, dado que darán prioridad a países que ya compraron como Estados Unidos, para el que ya tienen “millones de dosis almacenadas”.

“Está claro que el retraso no limitará la cantidad total, ralentizará la entrega”, dijo Stéphane Bancel en una entrevista con AFP al referirse a Europa.

Por el contrario, Estados Unidos tiene reservadas 100 millones de dosis desde principios de agosto, y “tenemos varios millones de dosis ya almacenadas” en el país, listas para ser entregadas a las autoridades estadounidenses en cuanto se autorice su comercialización, probablemente en diciembre.

Moderna anunció esta semana que su vacuna experimental es casi 95% efectiva para proteger a las personas del coronavirus, lo que aumenta aún más las esperanzas de poner fin a la pandemia después de que Pfizer/BioNTech publicara hallazgos similares la semana pasada sobre su vacuna.

Desde el verano, Moderna entabló negociaciones con la Comisión Europea sobre la compra de 80 millones de dosis de la vacuna, pero no se ha firmado ningún contrato, dijo Bancel desde la sede de la empresa en Cambridge, Massachusetts.

Mientras tanto, Moderna, que desarrolló su medicamento en conjunto con los Institutos Nacionales de Salud de Estados Unidos, ha firmado acuerdos para suministrar la vacuna a Canadá, Japón, Israel, Catar y Reino Unido.

ES DE INTERÉS |

A un año del primer caso de Covid, el mundo alista vacunación

Moderna supera logros de Pfizer y Sputnik